The cathelicidin anti-microbial peptide LL-37 is involved in the reepithelialization of human skin wounds and is lacking in chronic ulcer epithelium. LL-37(human) is a cathelicidin-derived peptide with antimicrobial and angiogenic activity. Antimicrobial peptide derivative of human cathelicidin.Antimicrobial peptide derivative of human cathelicidin. Induces FPRL1-mediated chemotaxis of human neutrophils,monocytes and T cells in vitro. Promotes wound healing following skin-targeted electroporation of a plasmid encoding hCAP-18/LL-37 in mice.
Also triggers apoptosis in colon cancer cells.
Product details
Product Name: LL-37
CAS No:597562-32-8
Sequence:ANTIBACTERIAL PROTEIN LL-37 AMIDE (HUMAN)
Molecular Formula: C205H341N61O52
Molecular Weight: 4492.27854g/mol
Specification: 5mg/vial;10mg/vial;15mg/vial
Purity : 98% HPLC
Appearance: White lyophilized Powder
Shelf Life:24 Months
Storage: Refrigeration keeps dry and away from light.
LL-37 is the only known human Cathelicidin is a big protein family where the members exhibit diverse functions.These peptides, essentially produced by macrophages and polymorphonuclear leukocytes (both types of white blood cells), have bactericidal action. They have been found to have shown other substantial effects as well. The entire group is often referred to as antimicrobial peptides (AMPs). LL-37 in particular has been found to play significant roles in autoimmune disease, cancer, and wound healing.
1.Reduce apoptotic death of keratinocytes.
2.Improve IFN-alpha synthesis.
3.Suppress signaling through toll-like receptor 4 (TLR4).
4.Modify chemotaxis of neutrophils and eosinophils.
5.Trigger IL-18 production, and reduce levels of atherosclerotic plaques
